Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield < sup > TM < /sup > ®) and BBV-152 (Covaxin < sup > TM < /sup > ®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study

CONCLUSIONS: Both vaccines elicited good immune response after two doses, although seropositivity rates and GMT of anti-spike antibody titre was significantly higher in Covishield compared to Covaxin recipients.PMID:34600747 | DOI:10.1016/j.vaccine.2021.09.055

Source: Vaccine - October 3, 2021 Category: Allergy & Immunology Authors: Awadhesh Kumar Singh Sanjeev Ratnakar Phatak Ritu Singh Kingshuk Bhattacharjee Nagendra Kumar Singh Arvind Gupta Arvind Sharma Source Type: research